Samrin F. Habbani

Dr. Samrin F. Habbani

Comparative Pathobiology, Purdue University West Lafayette, West Lafayette, Indiana, USA
orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 June 2025 in Cancers
Verified
Journal Article
Open access
PDF file
FMFatema Mahjabeen
Fatema Mahjabeen
SHSamrin F. Habbani
Samrin F. Habbani
Sulma I. MohammedSulma I. Mohammed
Sulma I. Mohammed
Breast cancer is the most prevalent malignancy among women and a leading cause of morbidity and mortality worldwide. Metastasis—the dissemination of tumor cells to distant organs—is the primary driver of breast cancer-related deaths, often leading to organ dysfunction and treatment resistance. While sentinel lymph nodes are the initial site of metastasis, the molecular mechanisms driving lymphatic spread are still not well understood. Multifarious questions remain on the role, requirement, and significance of the lymphatic system in the context of the distant metastasis of breast cancer. To address these questions, this review explores the recent advancements achieved in studies related to the molecular processes behind lymphatic metastasis in breast cancer, highlighting the tumor microenvironment’s role in supporting circulating tumor cells. We also examine the key molecular pathways involved in metastatic progression by analyzing the cellular, genetic, and physiological factors that drive lymphatic metastasis. The insights gained may contribute to the development of new therapeutic approaches to prevent or mitigate breast cancer metastasis.

24 May 2025 in Cancers
Verified
Journal Article
Open access
PDF file
SHSamrin F. Habbani
Samrin F. Habbani
Sayeh DowlatshahiSayeh Dowlatshahi
Sayeh Dowlatshahi
NLNathanael Lichti
Nathanael Lichti
MBMeaghan Broman
Meaghan Broman
LTLucy Tecle
Lucy Tecle
Sulma I. MohammedSulma I. Mohammed
Sulma I. Mohammed
Background/Objectives: Cervical cancer (CC) is a significant global health challenge, particularly in low- and middle-income countries (LMICs), where limited access to human papillomavirus (HPV) vaccination and effective CC screening results in a majority of cases and fatalities among women. Moreover, existing vaccines do not target HPV-independent cancers. Current screening methods are expensive and time-consuming, with a limited emphasis on CC protein biomarkers. Therefore, we aimed to validate critical markers that allow the development of affordable point-of-care screening tests for resource-limited settings. Methods: This study first optimized a cell lysis and protein extraction protocol for CC cell lines and clinical cervical swabs. Subsequently, four proteins—topoisomerase II alpha (TOP2A), minichromosome maintenance complex component 2 (MCM2), valosin-containing protein (VCP), and cyclin-dependent kinase inhibitor 2A (p16INK4a)—were quantified in the resulting lysates using enzyme-linked immunosorbent assays, as well as in cervical tumors and squamous intraepithelial lesions (SILs) using immunohistochemistry for further validation. Results: Acetone precipitation allowed for efficient cell isolation, and radioimmunoprecipitation assay buffer yielded the highest protein recovery. VCP and p16INK4a were overexpressed across all cancer cell lines compared to primary cells. All four biomarkers were overexpressed in high-grade SIL (HSIL) swab specimens and tumor samples, including CC subtypes, G1–G3 tumor grades, and HSILs. Lastly, we showed that the proteins could accurately classify swabs and tissue specimens into clinically relevant groups. Conclusions: The quantitative analysis of these biomarkers, along with the subsequent sensitive and specific clinical classification, highlights their potential application in SIL early detection and CC prevention, particularly in LMICs.

1 November 2025 in International Journal of Women's Health
Verified
Journal Article
Open access
PDF file
SHSamrin F. Habbani
Samrin F. Habbani
ZYZehan Yang
Zehan Yang
MMMajed Mohammad
Majed Mohammad
MHMaram M Hamid
Maram M Hamid
RARaheeq Alfadil
Raheeq Alfadil
HWHelen Wu
Helen Wu
Purpose: Triple-negative breast cancer (TNBC) is an aggressive subtype with limited treatment options and a poor prognosis. Data on TNBC in Sudan are scarce. This study assessed the prevalence and predictors of TNBC and other molecular subtypes (Luminal A, Luminal B, and HER2-enriched) in relation to histopathological patterns, age at diagnosis, and sociodemographic risk factors. Methods: A retrospective, single-center study was conducted of 1480 women diagnosed with breast cancer between 2016 and 2021. Histological subtypes included carcinoma in situ (CIS), invasive ductal carcinoma (IDC), invasive lobular carcinoma (ILC), or medullary carcinoma (MC). Estrogen receptor (ER), progesterone receptor (PR), and HER2 status were determined by immunohistochemistry. Multivariate logistic regression identified predictors of TNBC. Results: TNBC accounted for 21% (n=307; mean age, 49 years) of all cases. Luminal A tumors represented 49% (n=722; mean age, 55), Luminal B 16% (n=237; mean age, 51), and HER2-enriched 14% (n=214; mean age, 50). TNBC was particularly frequent in MC (77%) compared to IDC (21%), CIS (20%), and ILC (15%). In multivariate analysis, younger age was a significant predictor of TNBC; each additional year of age reduced the odds by approximately 3% (Adjusted Odds Ratio [AOR]=0.97; 95% CI: 0.96– 0.99; p< 0.001). Histological subtype was also a significant determinant, with MC showing the strongest association with TNBC compared to other diagnoses. Conclusion: TNBC is highly prevalent among Sudanese women, especially those younger than 50 years and those with MC. These findings underscore the importance of early diagnosis and wider access to molecular profiling to guide treatment in low-resource settings.